• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Daily Dose: Vaccination Reduces Risk of Long COVID in Children

Daily Dose: Vaccination Reduces Risk of Long COVID in Children / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on findings from a study published in Pediatrics that examined vaccine effectiveness (VE) against long COVID in children aged 5-17 years.

The study

Researchers analyzed electronic health record data from 17 health systems in the RECOVER PCORnet program to assess vaccine effectiveness against long COVID in 2 groups of patients—aged 5-11 years and 12-17 years—as well as the time period in which patients were impacted. They adjusted for sex, ethnicity, health system, comorbidity burden, and pre-exposure health care utilization. They examined diagnosed long COVID as well as probable, or symptom-based long COVID, in the year following participant’s vaccination.

The cohort totaled 1 037 936 children, with 480 498 children in group 1 (aged 5-11 years) and 719 519 adolescents in group 2 (aged 12-17 years). Overall, 55% received at least 1 SARS-CoV-2 vaccine, and 84% of vaccinated participants received ≥2 doses.

The findings

Results showed that the incidence of probable long COVID in the cohort was 4.5% and the incidence of diagnosed long COVID was 0.7%. Investigators estimated that vaccine effectiveness within 12 months against long COVID was 35.4% among children with probable long COVID and 41.7% among those diagnosed with long COVID.

Investigators found that vaccine effectiveness was higher for adolescents aged 12-17 years (50.3%) than children aged 5-11 years (23.8%), and higher at 6 months (61.4%) than at 18 months (10.6%).

Authors' comment

"Our results provide substantial evidence in a large and diverse cohort of children receiving health care for protective effect in children 5 years and older. This study adds to the growing body of knowledge about mitigating effect of vaccines on COVID-19, while demonstrating the need for further research utilizing a range of designs to examine the protective effect of these vaccines against subsequent strains and to help guide vaccine policy."

Click here for more details.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
© 2024 MJH Life Sciences

All rights reserved.